Related Experiment Video
Updated: May 25, 2025

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
Reports of Encephalopathy Among Children with Influenza-Associated Mortality - United States, 2010-11 Through 2024-25
Amara Fazal1, Katie Reinhart1, Stacy Huang1
1Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.
Insights
Severe influenza-associated encephalopathy or encephalitis (IAE) in children, including acute necrotizing encephalopathy (ANE), has been reported. Early evaluation, testing, and antiviral treatment are crucial for suspected cases.
Area of Science:
- Pediatric Neurology
- Infectious Diseases
- Public Health Surveillance
Background:
- Anecdotal reports of severe influenza-associated acute necrotizing encephalopathy (ANE) in children emerged in early 2025.
- Influenza-associated encephalopathy or encephalitis (IAE) is a serious complication of influenza infection in pediatric populations.
- Existing surveillance systems may not fully capture the incidence of IAE and ANE.
Purpose of the Study:
- To examine trends in influenza-associated encephalopathy or encephalitis (IAE) among pediatric deaths.
- To analyze the demographic and clinical characteristics of children with fatal IAE.
- To inform healthcare providers about the recognition and management of IAE/ANE.
Main Methods:
- Analysis of pediatric influenza-associated deaths from the 2010-11 through 2024-25 influenza seasons.
- Review of case data for the presence of influenza-associated encephalopathy or encephalitis (IAE).
- Contacting state health departments for specific case ascertainment, including ANE diagnoses.
Main Results:
- IAE was identified in 9% (166/1840) of pediatric influenza-associated deaths across seasons (2010-11 to 2024-25).
- Preliminary 2024-25 data show 13% (9/68) of pediatric influenza deaths had IAE.
- Patients with fatal IAE were median 6 years old, 54% had no underlying conditions, and 20% were vaccinated.
Conclusions:
- Influenza-associated encephalopathy or encephalitis (IAE) represents a significant proportion of pediatric influenza deaths.
- Healthcare providers should maintain a high index of suspicion for IAE in children with acute febrile illness and neurological symptoms.
- Prompt diagnosis, influenza testing, neuroimaging, antiviral therapy, and supportive care are critical. Annual influenza vaccination is recommended.
Abstract:
In late January 2025, CDC received anecdotal reports of children with influenza-associated acute necrotizing encephalopathy (ANE), a severe form of influenza-associated encephalopathy or encephalitis (IAE), including several fatal cases. In response, CDC examined trends in the proportions of cases with IAE among influenza-associated pediatric deaths reported during the 2010-11 through 2024-25 influenza seasons, including demographic and clinical characteristics of identified cases. CDC contacted state health departments to ascertain whether any pediatric influenza-associated deaths with IAE reported this season also had a diagnosis of ANE. Among 1,840 pediatric influenza-associated deaths during the 2010-11 through 2024-25 influenza seasons, 166 (9%) had IAE, ranging from 0% (2020-21 season) to 14% (2011-12 season); preliminary data for the 2024-25 season (through February 8, 2025) indicate that nine of 68 (13%) had IAE. Across seasons, the median age of patients with fatal IAE was 6 years; 54% had no underlying medical conditions, and only 20% had received influenza vaccination. Because no dedicated national surveillance for IAE or ANE exists, it is unknown if the numbers of cases this season vary from expected numbers. Health care providers should consider IAE in children with acute febrile illness and neurologic signs or symptoms lasting >24 hours. Evaluation should include testing for influenza and other viruses and neuroimaging; clinical management should include early antiviral treatment for suspected or confirmed influenza and supportive critical care management as needed. Influenza vaccination is recommended for all eligible persons aged ≥6 months as long as influenza viruses are circulating.
More Related Videos
08:52Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
10:47Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant Mice
Published on: April 14, 2011
Related Concept Videos
Vaccinations
Viral Mutations